“It is very clear that the Breast Cancer Research Foundation has already made a significant impact

On the course of breast cancer research.”

Larry Norton, MD, Medical Director, Evelyn H. Lauder Breast Center, Memorial Sloan

Kettering Cancer Center; BCRF Scientific Director

The BREAST CANCER RESEARCH FOUNDATION was founded in 1993 by the late Evelyn H. Lauder as an independent, not-for-profit 501 (c)(3) organization dedicated solely to funding innovative clinical and translational research. BCRF stands today as the most highly rated and largest private funder of breast cancer research worldwide. The mission of the Foundation is two-fold: cure and prevention. Determined to continue our Founder’s philanthropic ambition and honor her lasting impact on research, BCRF is deeply committed to eradicating existing metastasis, and stopping cancers before they happen by discovering how they happen.

Breast cancer is the most common form of cancer (after skin cancer) in women in the United States, with a new diagnosis every 2 minutes. The American Cancer Society estimates that 249,260 new cases of invasive breast cancer will be diagnosed in 2016 in US women and men, and 40,890 people will die from disease. These statistics, and the fact that clinical research continues to be under-funded, explains the critical need the Breast Cancer Research Foundation and its laser-sharp focus on achieving our ultimate goal of prevention and cure.

In 2016-2017, the Foundation is supporting more than 250 scientists worldwide with grants totaling #57 million. This figure includes $56 through BCRF’s annual research grants and $1 million committed to the Evelyn H. Lauder Founder’s Fund, a global initiative focused on unraveling the biology of metastasis, which enables our researchers to make significant progress that will impact the resolution of not only breast but many other cancers.

By investing in people instead of projects, we give our grantees the funds and the freedom to explore their best ideas. The leadership of that process is key and BCRF’s esteemed Scientific Advisory Board is comprised of internationally recognized, geographically and disciplinarily diverse scientists, who ensure that our global brain-trust of researchers are efficiently tackling breast cancer from every angle. BCRF-funded investigators are engaged in studies aimed at advancing knowledge on cancer biology, developing novel targeted therapies to yield greater patient benefits, and creating new diagnostic and prognostic tools. TO bolster progress in the clinical setting, BCRF recently launched a first-of-its-kind Investigator-Initiated Drug Research Collaborative, which is devoted to bridging the gap between academic investigators and access to drugs in development, promising to propel research forward, faster. Everyday our grantees are designing more effective treatments and more sophisticated preventative strategies, and uncovering new and invaluable insights into how to eradicate cancer.

BCRF is a careful steward of our donors’ generosity, keeping administrative costs as low as possible. In fiscal 2016, 91% of every dollar raised was directed to research and awareness programs. As a result, the Foundation has received the highest ratings from monitoring agencies: 4 out of 4 stars from Charity Navigator, and “A+” from Charity Watch, formerly known as The American Institute of Philanthropy.

The Foundation welcomes and depends on contributions from all those concerned with breast health.

For more information, please call 646-497-2600 (toll-free, 1-866-FIND-A-CURE),

Or visit the Foundation web site: